No Data
Earnings Troubles May Signal Larger Issues for Enwei Pharmaceutical (SZSE:301331) Shareholders
Enwei Pharmaceuticals: Report for the third quarter of 2024
Enwei Pharmaceutical (301331.SZ) released its performance for the first three quarters, with a net income of 22.02 million yuan, a year-on-year decrease of 69.81%.
Enwei Medicine (301331.SZ) disclosed the third quarter report of 2024, achieving revenue of 5....
Enwei Pharmaceuticals (301331.SZ) has accumulated repurchased 3.0258% of its shares, costing 0.102 billion yuan.
Announcement from Enwei Pharmaceutical (301331.SZ), the company traded through centralized bidding as of September 30, 2024...
Subdued Growth No Barrier To Enwei Pharmaceutical Co., Ltd. (SZSE:301331) With Shares Advancing 26%
Enwei Medicine (301331.SZ): The core product "Jieeryin Solution" has continuously ranked first in the market share of the "inflammatory subcategory" in the chinese urban retail pharmacies' chinese patent medicine field for multiple years.
Galun Hui, September 24th - On the investor relations event, Enwei Medicine (301331.SZ) stated that its core product 'JIE'er Yin Wash Liquid' has ranked first in the 'Inflammation Sub-category' market for many years in the field of chinese patent medicine in urban retail pharmacies in China, and also for the first time in the first half of 2023, it made it to the top of the 'Urban Physical Pharmacy Terminal Gynecological Chinese Patent Medicine Brand Rankings'. The company intervened in zero-added products early and developed products such as 'Herbal Antibacterial Wash Liquid' and 'Female Care Liquid', gaining market recognition with good product strength. In addition, focusing on female health care, leveraging the JIE'er Yin brand, the company has also developed a bubble.
Enwei Pharmaceutical Co., Ltd. (SZSE:301331) Stock's On A Decline: Are Poor Fundamentals The Cause?
